Aptinyx to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, March 23, 2022

Rhea-AI Summary

Aptinyx Inc. (NASDAQ: APTX) will host a conference call and webcast on March 23, 2022, at 5:00 p.m. ET to discuss Q4 and full year 2021 financial results and recent business updates. Investors can participate by dialing (844) 200-6205 domestically or (929) 526-1599 internationally, using conference ID 768426. The event will also be accessible via their website. Aptinyx is focused on developing therapies for brain and nervous system disorders with three candidates in clinical development.

Positive

• Aptinyx is advancing three product candidates targeting chronic pain, PTSD, and cognitive impairment.
• The company has a proprietary platform for developing NMDA receptor modulators.

Negative

• None.

EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 23, 2022 at 5:00 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights.

To access the live conference call, please dial (844) 200-6205 (domestic) or (929) 526-1599 (international) and refer to conference ID 768426. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005435/en/

Investor & Media Contact:

Patrick Flavin

Aptinyx Inc.

ir@aptinyx.com or corporate@aptinyx.com

847-871-0377

Source: Aptinyx Inc.

FAQ

What are the financial results that Aptinyx will report on March 23, 2022?

Aptinyx will discuss its fourth quarter and full year 2021 financial results during the conference call.

How can I access the Aptinyx conference call on March 23, 2022?

You can access the call by dialing (844) 200-6205 for domestic calls or (929) 526-1599 for international calls, using conference ID 768426.

What is Aptinyx's focus as a biopharmaceutical company?

Aptinyx focuses on developing therapies for brain and nervous system disorders, utilizing a platform for NMDA receptor modulators.

What candidates are in Aptinyx's clinical development pipeline?

Aptinyx has three product candidates aimed at chronic pain, post-traumatic stress disorder, and cognitive impairment.